{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:31Z","timestamp":1740107791668,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10147-022-02199-5","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T17:02:37Z","timestamp":1659200557000},"page":"1439-1449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-0315","authenticated-orcid":false,"given":"Toshihiro","family":"Nakao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideya","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syoko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol 25:1670\u20131676. https:\/\/doi.org\/10.1200\/JCO.2006.09.0928","journal-title":"J Clin Oncol"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609\u20131618. https:\/\/doi.org\/10.1056\/nejmoa1403108","journal-title":"N Engl J Med"},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9","journal-title":"Lancet Oncol"},{"key":"2199_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"key":"2199_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141. https:\/\/doi.org\/10.1002\/jbmr.5650090802","journal-title":"J Bone Miner Res"},{"key":"2199_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12491","author":"T Kamada","year":"2021","unstructured":"Kamada T, Furukawa K, Takahashi J et al (2021) Prognostic significance of osteopenia in patients with colorectal cancer: a retrospective cohort study. Ann Gastroenterol Surg. https:\/\/doi.org\/10.1002\/ags3.12491","journal-title":"Ann Gastroenterol Surg"},{"key":"2199_CR7","unstructured":"High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia \u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/11745299\/. Accessed 1 Nov 2021"},{"key":"2199_CR8","doi-asserted-by":"publisher","unstructured":"Satake H, Sunakawa Y, Miyamoto Y, et al (2018) A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget 9:18811\u201318820. https:\/\/doi.org\/10.18632\/ONCOTARGET.24702","DOI":"10.18632\/ONCOTARGET.24702"},{"key":"2199_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000337225","volume":"82","author":"Y Sunakawa","year":"2012","unstructured":"Sunakawa Y, Fujita KI, Ichikawa W et al (2012) A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1\/*1,*1\/*6 or *1\/*28. Oncology 82:242\u2013248. https:\/\/doi.org\/10.1159\/000337225","journal-title":"Oncology"},{"key":"2199_CR10","unstructured":"Cancer Institute N (2017) Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0"},{"key":"2199_CR11","doi-asserted-by":"publisher","unstructured":"Toshima T, Yoshizumi T, Ikegami T, et al (2018) Impact of osteopenia in liver cirrhosis: special reference to standard bone mineral density with age. Anticancer Res 38:6465\u20136471. https:\/\/doi.org\/10.21873\/anticanres.13009","DOI":"10.21873\/anticanres.13009"},{"key":"2199_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/lt.24458","volume":"22","author":"P Sharma","year":"2016","unstructured":"Sharma P, Parikh ND, Yu J et al (2016) Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. Liver Transpl 22:1092\u20131098. https:\/\/doi.org\/10.1002\/lt.24458","journal-title":"Liver Transpl"},{"key":"2199_CR13","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","volume":"8","author":"WM Hryniuk","year":"1990","unstructured":"Hryniuk WM, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8:1935\u20131937. https:\/\/doi.org\/10.1200\/JCO.1990.8.12.1935","journal-title":"J Clin Oncol"},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"2199_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jare.2014.01.011","volume":"6","author":"WZ Mostafa","year":"2013","unstructured":"Mostafa WZ, Hegazy RA (2013) Vitamin D and the skin: focus on a complex relationship: a review. J Adv Res 6:793\u2013804","journal-title":"J Adv Res"},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cam4.3638","volume":"10","author":"H Osumi","year":"2021","unstructured":"Osumi H, Shinozaki E, Ooki A et al (2021) Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer Med 10:615\u2013625. https:\/\/doi.org\/10.1002\/cam4.3638","journal-title":"Cancer Med"},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00280-010-1487-6","volume":"68","author":"K Shitara","year":"2011","unstructured":"Shitara K, Matsuo K, Oze I et al (2011) Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol 68:301\u2013307. https:\/\/doi.org\/10.1007\/s00280-010-1487-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"2199_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11154-010-9154-0","volume":"11","author":"G Karaguzel","year":"2010","unstructured":"Karaguzel G, Holick MF (2010) Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord 11:237\u2013251","journal-title":"Rev Endocr Metab Disord"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02199-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T03:31:36Z","timestamp":1661139096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02199-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02199-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"30 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Ethics Committee of Tokushima University, Approval No. 3215-1. Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}}]}}